Results 171 to 180 of about 6,071 (199)

Evaluation of the Safety of Palivizumab in the Second Season of Exposure in Young Children at Risk for Severe Respiratory Syncytial Virus Infection

Drug Safety, 2012
Thierry Lacaze-Masmonteil, Ian Mitchell, Martin Cihar   +2 more
exaly  

Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants

Human Vaccines and Immunotherapeutics, 2014
Michael L Forbes, Xionghua Wu, Christopher S Ambrose   +2 more
exaly  

Utilization and efficacy of palivizumab for children with Down syndrome

Pediatrics International, 2020
Masato Takeuchi, Koji Kawakami
exaly  

The cost effectiveness of palivizumab: a systematic review of the evidence

Journal of Medical Economics, 2010
Kelly Smart, Krista L Lanctôt, Bosco Paes   +2 more
exaly  

Palivizumab/ribavirin

Reactions Weekly, 2023
openaire   +1 more source

Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants

Infectious Diseases and Therapy, 2017
Sally W Wade, Kimmie K Mclaurin
exaly  

Palivizumab

2016
openaire   +1 more source

Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants

Journal of Paediatrics and Child Health, 2002
Keith Grimwood, Catherine A Byrnes
exaly  

Treatment of respiratory syncytial virus with palivizumab: a systematic review

World Journal of Pediatrics, 2010
Jia Hu, Joan L Robinson, Robinson Joan L   +2 more
exaly  

Palivizumab

Reactions Weekly, 2010
openaire   +1 more source